FK 633

Drug Profile

FK 633

Alternative Names: FR 144633

Latest Information Update: 02 Oct 2001

Price : $50

At a glance

  • Originator Fujisawa
  • Class Antiplatelets; Small molecules; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Coronary artery restenosis; Thrombosis

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Coronary artery restenosis in Japan (Unknown route)
  • 02 Oct 2001 No-Development-Reported for Thrombosis in Japan (IV)
  • 05 Aug 1999 Phase-II clinical trials for Thrombosis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top